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Abstract
Transient receptor potential melastatin 4 (TRPM4) is a broadly expressed Ca2+ activated monovalent
cation channel that contributes to the pathophysiology of several diseases.
For this study, we generated stable CRISPR/Cas9 TRPM4 knockout (K.O.) cells from the human prostate
cancer cell line DU145 and analyzed the cells for changes in cancer hallmark functions. Both TRPM4-K.O.
clones demonstrated lower proliferation and viability compared to the parental cells. Migration was also
impaired in the TRPM4-K.O. cells. Additionally, analysis of 210 prostate cancer patient tissues demon-
strates a positive association between TRPM4 protein expression and local/metastatic progression. More-
over, a decreased adhesion rate was detected in the two K.O. clones compared to DU145 cells.
Next, we tested three novel TRPM4 inhibitors with whole-cell patch clamp technique for their potential to
block TRPM4 currents. CBA, NBA and LBA partially inhibited TRPM4 currents in DU145 cells. However,
none of these inhibitors demonstrated any TRPM4-specific effect in the cellular assays.
To evaluate if the observed effect of TRPM4 K.O. on migration, viability, and cell cycle is linked to TRPM4
ion conductivity, we transfected TRPM4-K.O. cells with either TRPM4 wild-type or a dominant-negative
mutant, non-permeable to Na+. Our data showed a partial rescue of the viability of cells expressing func-
tional TRPM4, while the pore mutant was not able to rescue this phenotype. For cell cycle distribution,
TRPM4 ion conductivity was not essential since TRPM4 wild-type and the pore mutant rescued the phe-
notype.
In conclusion, TRPM4 contributes to viability, migration, cell cycle shift, and adhesion; however, blocking
TRPM4 ion conductivity is insufficient to prevent its role in cancer hallmark functions in prostate cancer
cells.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecom-
mons.org/licenses/by/4.0/).
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Background
Each year around 1.3 million men worldwide are
diagnosed with prostate cancer.1 After lung cancer,
prostate cancer is the most frequently diagnosed
malignancy in men, and it is the fifth leading cause
of cancer-related death in men.1 Androgen depriva-
tion therapy (ADT) is commonly used as initial
treatment of prostate cancer. This therapy can be
initially efficient, however, most cases develop
resistance to ADT and transform into castration-
resistant prostate cancer (CRPC). In that case,
chemotherapy is the preferred continued treat-
ment, but CRPC also tends to develop resistance
to the chemotherapeutic drugs and transform into
dual-resistant prostate cancer. Therefore, with the
frequent transformation of prostate cancer into
CRPC, the need for new therapies is growing.2,3
In a recent study, Berg and colleagues
demonstrated a positive correlation between
transient receptor potential melastatin 4 (TRPM4)
channel protein overexpression in combination
with a high histoscore (H-score) and increased
risk of recurrence after radical prostatectomy.4
Moreover, another study aimed at identifying
cancer-driver genes for prostate cancer described
TRPM4 as a cancer-driver gene in androgen-
independent prostate cancer cells.5
TRPM4 is a Ca2+ activated monovalent cation
channel, which belongs to the family of transient
receptor potential (TRP) channels. TRPM4 is
widely expressed in various organs, although its
expression is the highest in prostate and colon.6
TRPM4 conducts monovalent cations, such as
Na+ and K+, without significant permeability toward
Ca2+.7 TRPM4 is involved in intracellular Ca2+ sig-
naling, as Na+ influx, after activation of TRPM4,
may depolarize the plasma membrane and thereby
decrease the driving force for Ca2+ influx via store-
operated Ca2+ entry (SOCE).8–13
Several studies comparing the expression levels
of TRPM4 in malignant prostate tissue and healthy
prostate glands reported that TRPM4 mRNA was
significantly elevated in tumor samples (reviewed
in [14]). Particularly, TRPM4 mRNA expression
levels were increased in premalignant human pro-
static intraepithelial neoplasia (PIN).15 TRPM4
was shown to contribute to the proliferation of pros-
tate and cervical cancer cells, through the activity
of GSK3b and b-catenin16,17 and was reported to
contribute to the migration and invasion of prostate
cancer cells.9,17,18 Additionally, a mass
spectrometry-based proteomics study found
TRPM4 to be associated with focal adhesion
(FA)-related proteins. In addition to its focal adhe-
sion localization, TRPM4 was reported to regulate
FA turnover.19,20 Recently, TRPM4 was identified
to be negatively regulated by microRNA-150
(miR150). Upregulation of miR150 resulted in inac-
tivation of b-catenin signaling and suppression of
epithelial mesenchymal transition (EMT) as well
as cell cycle shift in PC3 prostate cancer cells.21
Due to its overexpression and involvement in
cancer hallmark functions of prostate cancer,
TRPM4 is an interesting drug target candidate.
However, due to the lack of selective and potent
inhibitors, TRPM4 has not yet been validated as
such. The two most commonly used inhibitors for
studies of TRPM4 to date are flufenamic acid and
9-phenanthrol. However, both have been reported
to have low potency22,23 and a long list of off-
targets.24 Therefore, new selective inhibitors are
required to accurately and efficiently study the role
of TRPM4 and its ion conductivity in different dis-
ease model systems. Recently, a new potent and
selective inhibitor of TRPM4, so-called compound
5 (4-chloro-2-(2-chlorophenoxy) acetamido)ben-
zoic acid, now named CBA), was discovered.25,26
CBA blocks TRPM4 current both in cells overex-
pressing TRPM4 and in the LNCaP prostate cancer
cell line, expressing endogenous TRPM4.26 More-
over, CBA showed good selectivity over other
TRP channel family members (TRPV1, TRPV3,
TRPV6, TRPM5, TRPM7, TRPM8).26
Here we investigate whether CBA or any of its
new derivative compounds are useful tools to
study the role of TRPM4 in prostate cancer and
could contribute to the development of new
clinical drug candidates. In this study, we show
impaired cell viability, migration, and changes in
cell adhesion in TRPM4 CRISPR/Cas9 knockout
(K.O.) cells. We investigated the underlying
mechanism with rescue cells expressing TRPM4
or a dominant negative construct, which is unable
to conduct Na+ (TRPM4-D984A).
Results
Decreased migration, proliferation, and
changes in cell cycle distribution in TRPM4
knockout cells
To study the impact of TRPM4 on viability and
migration in prostate cancer cells, we generated
stable TRPM4-K.O. cells from the DU145
prostate cancer cell line using CRISPR/Cas9
technique. In TRPM4-K.O. clones 1 and 2,
TRPM4 protein and mRNA expression were
absent (Supplementary Figure S1a and b).
TRPM4-specific currents have been identified in
DU145 in the past,9 but due to technical limitations
of the TRPM4 siRNA downregulation, the propor-
tion of TRPM4 in Ca2+ activated non-selective cur-
rent (ICAN) remained unclear. TRPM4 currents
were evoked with 10 mM Ca2+ in the patch pipette
in whole-cell patch clamp configuration. Currents
were extracted at80 mV and +80 mV (normalized
to cell capacitance) and plotted as current density
(CD) versus time (Figure 1a). Under these condi-
tions, a current of ~40 pA/pF developed in
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DU145. The current–voltage relationship curve (IV)
at t = 394 s, displaying a positive reversal potential
characteristic of TRPM4, can be seen as an inset in
Figure 1a. Upon replacement of Na+ in the bath
solution with the impermeable cation NMDG+ (at
t = 400 s), the inward current was inhibited, demon-
strating that the recorded currents were carried by
monovalent Na+ ions. Current development was
absent in TRPM4-K.O. clones 1 and 2, indicating
that in DU145 ICAN is carried exclusively by TRPM4
(Figure 1a).
Impairment of TRPM4 decreased migration in
other prostate cancer cell systems.9,17,21 To inves-
tigate migration in our DU145 K.O. system, we set
up a fluorescence-based transwell migration assay
with FCS as chemoattractant (Figure 1b). As
Figure 1. TRPM4 knockout affects important cellular functions in DU145. (a) Whole-cell patch clamp data from
DU145 and two K.O. clones (clones 1 and 2). Currents were evoked with 10 mM Ca2+ in the patch pipette and
normalized to cell size. NMDG+ was applied on cells at t = 400 s. Current density (CD), displayed as mean +/ SEM,
is plotted versus time. Inset: extracted current-voltage relationship curves (IVs) at t = 394 s in black and during
NMDG+ application at t = 408 s in gray (n = 6 for DU145, n = 6 for clone 1, n = 5 for clone 2). (b) Transwell migration
assay of DU145 and TRPM4-K.O. clones 1 and 2: relative fluorescence was recorded over 25 h and plotted versus
time. (c) Bar graph of data in (b) at 15 and 25 h displayed as mean + SEM, duplicates, n = 3. (d) Cell viability of DU145
and clones 1 and 2 evaluated with RealTime-Glo MT assay, plotted over time as relative luminescence, normalized to
the value at t = 0. (e) Bar graph of data from (d) at 24, 48, and 72 h, displayed as mean + SEM, triplicates, n = 3. (f)
Cell confluence was evaluated with the IncuCyte imaging system. Images were acquired every 30 min over 24 h and
confluence in % was plotted versus time. (g) Bar graph of cell confluence data from (f) plotted as mean + SEM, n = 3.
(h) Representative propodium iodide (PI)-staining histograms. Cell cycle distribution displayed in % of cells, as mean
of seven independent experiments. For all assays above, a value of p < 0.05 was considered statistically significant.
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displayed in Figure 1c, migration was decreased in
clones 1 and 2 (23–43%) compared to the parental
cell line at the indicated time points. The effect of
TRPM4 K.O. on migration was confirmed with a
label-free migration assay on the xCELLigence
RTCA DP system. Here, the migration was strongly
decreased by 36–66% after 10 h, with a 49–79%
slower slope at 5–10 h in both K.O. clones (signifi-
cant for clone 2) compared to DU145 (Supplemen-
tary Figure S2a–c).
Next, the effect of TRPM4 knockout on cell
viability and proliferation was evaluated
(Figure 1d–g). Cell viability was determined with a
real-time kinetic assay over 72 h. TRPM4-K.O.
clones 1 and 2 displayed lower viability compared
to DU145 cells (Figure 1d). After 72 h, the two K.
O. clones demonstrated 38% lower viability
compared to the parental cells (Figure 1e).
Proliferation was evaluated in real time with the
IncuCyte S3 system and was read out as
increased cell confluence against time (Figure 1f).
Proliferation was reduced in both TRPM4-K.O.
clones compared to DU145 after 10 and 20 h with
30–37% reduction at 20 h (Figure 1g).
Cell cycle distribution plays an important role in
the regulation of proliferation, and TRPM4 has
been shown to affect cell cycle distribution in the
past.21,27,16 Therefore, cell cycle distribution of
DU145 and TRPM4-K.O. clones was determined
with PI staining and flow cytometry. Clone 1 dis-
played a tendency for more cells in G1-phase com-
pared to DU145 (Figure 1h). This is in line with
previously published data from another prostate
cancer cell line,21 and data from cervical16 and col-
orectal cancer cells.27 However, in clone 2 an
increase in G2-phase and a slight decrease in
G1-phase were detected.
Altogether, as previously published for other
cellular prostate cancer systems, DU145 TRPM4
CRISPR/Cas9 K.O. clones show a reduction in
cancer hallmark functions cell viability,
proliferation, migration and a slight shift in cell
cycle.
TRPM4 knockout results in impaired cell
adhesion
Corresponding to the above experiments,
proliferation was decreased by 34–41% at 48 h
compared to the parental cells in the label-free
proliferation assay from xCELLigence (Figure 2a
and Supplementary Figure S2d and e). In addition
to the above findings on proliferation, the
impedance-based xCELLigence assay revealed a
discrepancy between the parental cells and the
two K.O. clones in the first 3–5 h (Figure 2b). It
should be noted that a proliferation cycle takes
~34 h for DU145 cells.28 Hence, the early differ-
ence (up to 5 h) is not the result of decreased pro-
liferation, but rather is connected to differences in
adhesion and cell spreading.29 Here we quantified
the differences in cell adhesion by calculating the
slope at 2–5 h. The two TRPM4-K.O. cell lines dis-
played up to 78% decreased adhesion rate when
compared to DU145 (Figure 2c).
To further investigate changes in cell adhesion
by TRPM4 knockout, we performed an image-
based assay. The IncuCyte assay allows
visualization and analysis of the adhesion
process. Cell adhesion of DU145 and TRPM4-K.
O. clones was quantified as cell confluence at
different time points (Figure 2d and e). Cells
adhering to the surface are more spread and
flatter than the non-adherent spherical cells.
Therefore, non-adherent cells will add less to the
total cell confluence. Moreover, these cells will
appear smaller. Clones 1 and 2 showed cell
confluence of 15–16% at 6 h compared to DU145
cells, which averaged 22% confluence (Figure 2d
and e). The average size of objects (cells) was
analyzed with the IncuCyte software.
Quantification of the average object size showed
a smaller size of clones 1 and 2 compared to
DU145 (Figure 2f), indicating that these cells are
less adherent or less spread on the well surface
than the parental cells. Figure 2g shows
representative images of DU145 cells (upper
panel), TRPM4-K.O. clone 1 (middle panel), and
TRPM4-K.O. clone 2 (lower panel) at 1.5 or 5 h
at 10x magnification (two left panels).
Enlargements of the same images are displayed
in the two right-hand panels. After 5 h, the two
TRPM4-K.O. clones were more spherical and
less adherent than the parental cells. Additionally,
the images indicate that most cells from the
parental cell line were adherent at 5 h.
Overall, our data suggest decreased adhesion
and cell spreading in the two TRPM4-K.O. clones
compared to DU145 cells.
Novel TRPM4 inhibitors block endogenous
TRPM4 currents
Recently, three small molecular inhibitors of
TRPM4, CBA ((4-chloro-2-(2-chlorophenoxy)
acetamido)benzoic acid), NBA (4-chloro-2-(1-naph
thyloxyacetamido)benzoic acid), and LBA (4-chl-
oro-2-(2-(4-chloro-2-methylphenoxy)propana
mido) benzoic acid)), have been described.25,26
CBA was previously positively evaluated as a
potent inhibitor of endogenous TRPM4 currents in
LNCaP prostate cancer cell line.26 For the purpose
of comparing our data and IC50-values with previ-
ous published data of CBA treated LNCaP cells
(IC50 for CBA 1.1 ± 0.3 lM), we here assess the
ability of CBA, NBA, and LBA to block endogenous
TRPM4 currents in LNCaP cells. TRPM4-specific
currents were evoked with 10 mM Ca2+ in the pip-
ette solution in whole-cell patch clamp configura-
tion. After current development (at t = 280 s),
3 mM of NBA, LBA, or CBA was applied for 120 s
(Figure 3a–c). After 400 s, standard bath solution
was applied to wash out the inhibitors. The TRPM4
current–voltage relationship (IV) before (t = 276 s)
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and during (t = 396 s) application of the inhibitor is
shown as an inset in the current density graphs
(Figure 3a–c). Each compound (LBA, NBA, and
CBA) inhibited TRPM4 currents at a dose of 3 mM
(Figure 3a–c). The calculated IC50 values from
the dose response curves were 0.74 ± 2.0 mM for
LBA and 0.16 ± 2.4 mM for NBA (Figure 3d and
e). Upon application of bath solution, the current
block by LBA and NBA was not reversible, while
the block by CBA was partly reversible (56% recov-
ered; Figure 3f). All IC50 values are in good agree-
ment with the IC50 values previously assessed with
Figure 2. Alterations of cell adhesion in TRPM4 knockout cells. (a) Cell proliferation was evaluated with impedance-
based xCELLigence system. Growth rates were plotted as cell index over 72 h. (b) First 8 h from graph (a) displayed.
(c) Bar graph of the slope at 2–5 h from (b). Data is presented as mean + SEM from four independent experiments. (d)
Cell confluence was analyzed with live-cell imaging system and plotted in % versus time. (e) Comparison of cell
confluence of DU145 and clones 1 and 2 at 2 and 6 h after seeding (1  105 cells per well). Each experiment was
repeated at least three times and is displayed as mean + SEM. (f) Average size of objects (cells) analyzed based on
the data collected in (d), and plotted as average size in lm2 over time 10 h as mean of three experiment. (g)
Representative images from (d) at 1.5 and 5 h post seeding. Right panel shows magnification of the images from the
left panel. Scale bar = 400 lm. p-value < 0.05 was considered significant.
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inside-out patch clamp recordings of excised mem-
branes from HEK293 TRPM4 overexpressing cells
and the IC50 of CBA in LNCaP.
26 Nevertheless, it is
worth mentioning that even at high doses (10 mM),
the remaining current was about 20–30% for all
three inhibitors.
Altogether, the three compounds block
endogenous TRPM4 currents in the LNCaP
prostate cancer cell line. None of the inhibitors
entirely blocked TRPM4 currents. While the block
with CBA was partly reversible, inhibition by LBA
und NBA was seemingly irreversible.
Evaluation of cellular functions with TRPM4
inhibitor treatment
Given the contribution of TRPM4 to cancer
hallmark functions, we next investigated the effect
of CBA on proliferation and migration. First, we
verified the ability of CBA to block the Ca2+
induced TRPM4 current in DU145 cells. At
concentrations of 3 and 50 mM, CBA blocked
55 ± 6% and 65 ± 7% of endogenous TRPM4
currents in the DU145 prostate cancer cell line
(Figure 4a and b). Next, the effect of CBA on
proliferation was evaluated in DU145 cells with
the label-free xCELLigence proliferation assay.
Cells were either untreated, treated with different
concentrations of CBA, or with DMSO as a
control. Figure 4c displays the cell index for each
condition after 20 h. A slight decrease in
proliferation was observed with the highest CBA
concentrations tested (25 mM). However, DMSO
control treatment also decreased proliferation,
and low concentrations of CBA did not block, but
seemingly induced a slight increase in
proliferation. We next evaluated the effect of CBA
on cell migration. Two different concentrations
(10 mM and 50 mM) were applied in a transwell
migration assay and a decrease in migration was
detected for cells treated with 50 mM CBA
(Figure 4d: over time; 4e: slope; and 4f: cell
index). Overall, only high doses (25 mM) of CBA
decreased proliferation and migration.
Figure 3. Novel TRPM4 inhibitors block endogenous TRPM4 in LNCaP cells. (a) Whole-cell patch clamp data from
LNCaP. Currents were evoked with 10 mM Ca2+ in the patch pipette and normalized to cell size. Current density (CD),
displayed as mean +/ SEM, is plotted versus time and 3 mM LBA was applied from 280–400 s. Inset: IV curves at
t = 196 s and t = 396 s (n = 12). (b) Same as (a) for NBA (n = 15). (c) Same as (a) for CBA (n = 6). (d) Average TRPM4
CD +/ SEM was plotted against LBA concentrations (n = 6 for 0.1 mM, n = 5 for 0.3 mM, n = 7 for 1 mM, n = 12 for
3 mM, n = 5 for 10 mM). Dose-response curve was fitted with a Hill equation and IC50 value was calculated to be
0.74 ± 2.0 mM. (e) Average TRPM4 CD +/ SEM plotted against NBA concentrations (n = 8 for 0.001 mM, n = 5 for
0.03 mM, n = 7 for 0.01 mM, n = 6 for 0.1 mM, n = 7 for 1 mM, n = 15 for 3 mM, n = 6 for 10 mM). Dose-response curve
was fitted with a Hill equation and IC50 value was calculated to be 0.16 ± 2.4 mM. (f) Evaluation of current densities
before application, during inhibitor treatment (3 mM), and after washout of the three inhibitors. Data normalized to the
CD before inhibitor application and displayed as mean + SEM.
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We next tested the TRPM4 specificity of this
effect. CBA was evaluated for its effect on
proliferation and migration in the two TRPM4-K.O.
clones. High doses (25 mM) of CBA decreased
proliferation of TRPM4-K.O. clones (Figure 5a:
clone 1; 5b: clone 2) similar to the parental
TRPM4-expressing DU145. The CBA-induced
decrease in proliferation, normalized to the DMSO
control, for DU145 and the two K.O. clones is
summarized in Figure 5c. No difference between
the parental DU145 and the two TRPM4-K.O.
clones was observed. Furthermore, the impact of
CBA on migration of TRPM4-K.O. cells was
evaluated. TRPM4-K.O. clones 1 and 2 were
treated with 10 and 50 mM CBA in a transwell
migration assay (Figure 5d). In both clones,
50 mM CBA decreased the migration to a similar
extent as in the parental DU145 cells (Figure 5e).
Finally, the effect of NBA and LBA in DU145 was
analyzed with patch clamp experiments. At a
concentration of 50 mM, NBA blocked 88 ± 9 % of
the endogenous TRPM4 currents in DU145
(Figure 5f) and 50 mM of LBA blocked 85 ± 7 %
of TRPM4 (Figure 5h). Next, the effect of NBA
and LBA on proliferation was analyzed in DU145
and the two TRPM4-K.O. clones. Here, no
significant impact on proliferation was observed at
any of the time points (Figure 5g and i).
In conclusion, compounds CBA, NBA, and LBA
partly blocked endogenous TRPM4 currents.
However, their effect on proliferation and migration
at very high doses is not specific to TRPM4.
TRPM4 ion conductivity is important for rescue
of cell viability
Our results show that the three TRPM4 blockers
failed to affect cellular functions. We hypothesized
that TRPM4 ion conductivity is not essential for
the effect on viability and migration observed with
the TRPM4-K.O. cells. To address the role of ion
conductivity in the observed viability and
migration phenotypes, we generated stable
TRPM4 re-expressing cells from the two TRPM4-
K.O. cell lines. Clones 1 and 2 were stably
transfected with either TRPM4 wild-type (TRPM4-
wt) or a dominant negative mutant TRPM4
(TRPM4-D984A), which forms a non-conductive
full-size protein.27,30 TRPM4 expression levels in
these cells were evaluated on protein and mRNA
level (Supplementary Figure S3), and the function-
ality of TRPM4 was confirmed with whole-cell patch
Figure 4. TRPM4 inhibitors evaluated for effects on migration and proliferation in DU145 cells. (a) Whole-cell patch
clamp data from DU145. Currents were evoked with 10 mM Ca2+ in the patch pipette and normalized to cell size. CD,
displayed as mean +/ SEM, is plotted versus time and 3 mM CBA was applied from 280–400 s (n = 6). Inset:
corresponding IV curves, t = 276 s shown in black and t = 396 s during 3 mM CBA application in blue. (b) Same as (a)
but with application of 50 lM CBA (n = 6). (c) Proliferation assay with CBA titration of 0–50 mM: cell index at 20 h is
plotted as mean + SEM. (d) Migration assay of DU145 with CBA treatment plotted as cell index versus time. (e) Slope
of cell index at 5–20 h from migration assay in (d) is plotted for control (DMSO), 10 mM, and 50 mM CBA. (f) Cell index
from migration assay in (d) is plotted at 10 and 20 h of migration. Migration assay was repeated at least four times in
triplicates. Values are displayed as mean + SEM.
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Figure 5. TRPM4 blockers in TRPM4-knockout cell lines. (a) Proliferation assay of clone 1 treated with 0–50 mM
CBA. Data is displayed as cell index at 20 h of treatment. (b) Same as (a) for clone 2. (c) Table of proliferation cell
index at 20 h upon inhibitor treatment for parental DU145, clones 1 and 2. Values are normalized to the cell index of
corresponding DMSO controls. (d) Transwell migration assay of clones 1 and 2 during CBA treatment of 10 and 50 mM
at 10 h of migration. (e) Table of migration cell index at 10 h upon inhibitor treatment of DU145, clone 1 and clone 2.
Values are normalized to the corresponding DMSO controls. (f) Whole-cell patch clamp data from DU145. Currents
were evoked with 10 mM Ca2+ in the patch pipette and normalized to cell size. CD, displayed as mean +/ SEM, is
plotted versus time and 50 mM NBA was applied from 280–400 s (n = 6). Inset: corresponding IV curves, t = 276 s
shown in black and t = 396 s during 50 mM NBA application in purple. (g) Proliferation assay with 50 mM NBA
treatment of DU145, clones 1 and 2. Cell index upon 40 or 60 h of inhibitor treatment is displayed. (h) Same as (f) for
50 mM LBA. (i) Same as (g) but with 50 mM LBA (n = 5). All cellular assays were repeated three times and are
displayed as mean + SEM.
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clamp experiments (Figure 6a–d). TRPM4-specific
currents were recovered in both K.O. clones re-
expressing TRPM4-wt, but not in cells expressing
TRPM4-D984A. Application of NMDG+ to the bath
solution (at t = 400 s) blocked the inward current,
confirming that the Ca2+ activated current was car-
ried by TRPM4-dependent Na+ influx.
Changes in viability were analyzed in TRPM4-K.
O. cells with re-expression of the two TRPM4
constructs. Re-expression of functional TRPM4-wt
caused partial recovery of viability in clone 1.
Expression of TRPM4-D984A, on the other hand,
was not able to recover the decrease in viability
observed in the TRPM4-K.O. cells (Figure 6e and
f). Cell migration could not be rescued with
TRPM4 re-expression in clone 1 (Figure 6g and
h). Rescue experiments with clone 2 were non-
conclusive (Figure 6i-l). Additional assays, such
as cell adhesion evaluated with impedance-based
assay (data not shown) and the imaged-based
cell confluence assay (see Supplementary
Figure S4), were inconclusive probably due to
changes in cell size and shape in the different
knockout and knock-in systems.
Next, cell cycle distribution was analyzed in cells
re-expressing TRPM4. Clone 1, with both re-
expressing TRPM4-wt and expression of TRPM4-
D984A, recovered the lower percentage of cells in
G1-phase, as seen in DU145 cells (Figure 7a and
b). The control cells expressing empty vector with
Figure 6. TRPM4 rescue experiment with clones 1 and 2. (a) Whole-cell patch clamp data of clone 1 transfected
with TRPM4-wt or TRPM4 dominant negative constructs (TRPM4-D984A), activated with 10 mM Ca2+ in patch pipette
(n = 5 for DU145, n = 4 for clone 1, n = 7 for clone 1 + TRPM4-wt, n = 7 for clone 1 + TRPM4-D984A). NMDG+ was
applied on cells at t = 400 s. (b) IVs at t = 396 s and during application of NMDG+ (t = 408 s). (c) Same as (a) for clone
2 (n = 5 for DU145, n = 5 for clone 2, n = 5 for clone 2 + TRPM4-wt, n = 4 for clone 2 + TRPM4-D984A). (d) Same as
(b) for clone 2. (e) Viability assay of DU145, clone 1, clone 1 + TRPM4-wt, clone 1 + TRPM4-D984A, and clone
1 + GFP measured over 72 h. (f) Bar graph of cell viability at 48 and 72 h for clone 1 rescue cells from experiment in
(e). (g) Transwell migration of DU145, clone 1, clone 1 + TRPM4-wt, clone 1 + TRPM4-D984A, and clone 1 + GFP.
Relative fluorescence plotted over 25 h. (h) Migration of cells from (g) at 15 and 25 h. (i) Viability assay of DU145,
clone 2, clone 2 + TRPM4-wt, clone 2 + TRPM4-D984A, and clone 2 + GFP measured over 72 h. (j) Bar graph of cell
viability at 48 and 72 h for clone 2 rescue cells from experiment in (i). (k) Transwell migration of DU145, clone 2, clone
2 + TRPM4-wt, clone 2 + TRPM4-D984A, and clone 2 + GFP. Relative fluorescence plotted over 25 h. (l) Migration of
cells from (k) at 15 and 25 h. Assays were repeated three times and are displayed as mean + SEM, and p-
value < 0.05 was considered significant.
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GFP remained unchanged in comparison to the
TRPM4-K.O. cells. For clone 2, no rescue effect
was observed with TRPM4-wt or with TRPM4-
D984A (Supplementary Figure S5).
In summary, TRPM4-wt could partially rescue the
viability phenotype, while TRPM4-D984A failed to
rescue the phenotype. In addition, TRPM4 was
able to rescue the cell cycle shift in G1-phase
observed in TRPM4-K.O. clone 1.
Expression of TRPM4 in prostate cancer tissue
Next, to investigate the association between
TRPM4 expression and disease progression, we
measured the expression of TRPM4 on a
prostate cancer tissue microarray (TMA)
assembled by the European Multicenter Prostate
Cancer Clinical and Translational Research
(EMPaCT) initiative.31 No association between
TRPM4 and overall survival probability was identi-
fied (Supplementary Figure S6a, pairwise compar-
ison using log-rank test in Supplementary
Table S1). While no association between TRPM4
expression and PSA or disease progression was
identified (Supplementary Figure S6b and c, pair-
wise comparison with log-rank test in Supplemen-
tary Tables S2 and S3), we found a positive
association between TRPM4 and local/metastatic
progression (log-rank pairwise adjusted p-
value = 0.05, between score 3 v.s. score 4, Supple-
mentary Figure S6d, Supplementary Table S4).
Discussion
Lately, interest in the role of ion channels in
cancer development and progression has
increased.32–35 Several TRP channel family mem-
bers have been reported to be overexpressed in
different types of cancer33 and TRPM8, TRPV6,
TRPC6, TRPV2, and TRPA1 have been shown to
be involved in prostate cancer progression.36 In
the last years, TRPM4, a member of the TRP chan-
nel superfamily, has received increasing interest for
its involvement in prostate cancer. TRPM4 has
been linked to migration of prostate cancer cell
lines.9,18,21 In this study, we confirm these findings
with a stable knockout system in DU145 cells. In
addition, reduced proliferation has been reported
in PC3 cells upon TRPM4 shRNA downregula-
tion.17,21 While another study reported no changes
in PC3 or DU145 upon siRNA downregulation,9 we
here report a strong decrease in both proliferation
and viability of DU145 TRPM4-K.O. cells. Further-
more, TRPM4 has been investigated for its poten-
tial as a biomarker for prostate cancer disease
progression. In 2015, Holzmann and colleagues
Figure 7. Cell cycle distribution after re-expression of TRPM4. (a) Representative histograms of the cell cycle
distribution of DU145, clone 1, clone 1 + TRPM4-wt, clone 1 + TRPM4-D984A, and clone 1 + GFP based on PI
staining. (b) Bar graph of cell cycle distribution of clone 1 re-expressing TRPM4-wt or D984A mutant presented as %
of cells + SEM from at least three independent experiments.
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analyzed TRPM4 tissue expression in a small
group of 20 prostate cancer patients.9 They
reported elevated TRPM4 expression in prostatic
intraepithelial neoplasia (PIN) compared to healthy
tissue. However, no correlation between TRPM4
and pathological stages or clinical outcome was
observed. One year later, in a bigger cohort study,
Berg et al. analyzed TRPM4 expression in tissue
samples from 614 prostate cancer patients.4 Here,
a significantly higher staining intensity of TRPM4
was reported in cancerous prostates compared to
matched benign glands. No direct significant corre-
lation between TRPM4 expression and risk of bio-
chemical recurrence was detected. However,
samples with an H-score equal to or above median,
in combination with high-intensity TRPM4 staining,
significantly correlated with an increased risk of bio-
chemical recurrence. In the current study we report
a positive correlation between TRPM4 staining
intensity (score 3 vs. score 4) and local/metastatic
progression.
As more studies show the potential involvement
of TRPM4 in prostate cancer pathophysiology,
there is a need for novel tools, such as selective
and potent inhibitors, to further study its role. In
this study, we evaluated three novel TRPM4
blockers for their potency to block the current of
endogenously expressed TRPM4 in prostate
cancer cells. The two CBA derivatives, LBA and
NBA,25,26 showed inhibitory effects on the Ca2+
activated TRPM4 current. Nevertheless, none of
these blockers had any TRPM4 specific effect on
prostate cancer cell proliferation or migration, pos-
sibly as the blockers did not inhibit the entire cur-
rent at low micromolar concentrations. In the case
of DU145, cells treated with 50 mM NBA or LBA still
retained 12–15% of the original current. Moreover,
the lack of effect on cell proliferation and migration
could indicate that TRPM4-mediated ion conductiv-
ity is not needed for the observed effect in knockout
and knockdown systems. Potentially the observed
effect is due to protein expression rather than the
activity of TRPM4. Nonetheless, our data from
experiments investigating DU145 TRPM4-K.O.
cells re-expressing TRPM4-wt or TRPM4-D984A
point to a role for TRPM4 current in cell viability.
A recent publication showed that TRPM4-
mediated ion conductivity is required for the rescue
of viability and cell cycle shift in a colorectal cancer
cell line.27 However, if this is also the case for pros-
tate cancer needs further investigation, including a
detailed analysis of SOCE, that is impaired upon
downregulation of TRPM4 and plays a pivotal role
in cancer cell progression.37,38 A previous study
showed a 50% increased Ca2+ entry rate and
20% higher Ca2+ plateau in DU145 TRPM4 knock-
down cells with only 40% transfection efficiency,
indicating that reduced TRPM4 currents may still
affect calcium signaling.9
Following this study it would be interesting to
analyze the differences in effect of blockers in
long term vs short term treatments. As we have
learned in this study, long term treatment of cells
displays a potential toxic effect on cells in the
highest concentrations (25–50 mM) which does
not seem to be TRPM4-specific. Possibly short
term treatment could be less harmful for the cells.
Changes in proliferation are often linked to
modifications of cell cycle progression. We
observed here a trend for shift in cell cycle
distribution of TRPM4-K.O. clone 1 with a higher
percentage of cells in G1-phase when compared to
DU145 cells. These alterations are in agreement
with recently published data on PC3 cells, for which
increased G1-phase and decreased S-phase in
TRPM4 depleted cells was reported.21
Consistent with the recent study by Hong et al.,
which reports morphological changes of PC3
prostate cancer cells upon TRPM4 inhibition with
miR-150 or siRNA silencing,21 we observed altered
morphology in TRPM4-depleted cells. DU145
TRPM4-K.O. cells appeared more elongated and
had more filopodia-like structures compared to
the more evenly shaped parental cells. TRPM4
was previously shown to localize in FA and to be
involved in FA turnover.19 Cáceres and colleagues
reported diminished cell size upon inhibition of
TRPM4 in mouse embryonic fibroblasts. In that
study, 9-phenanthrol-treated cells displayed dimin-
ished lamellipodia-like actin distribution, suggesting
involvement in cell spreading and cytoskeleton
reorganization. Based on our impedance-based
cellular assay and image-based analysis, we here
report a decrease in adhesion of cells without
TRPM4 expression. To our knowledge, this is the
first time that TRPM4 has been shown to be
involved in cell adhesion through a quantificational
experimental setup.
The increasing evidence for the involvement of
TRPM4 in prostate cancer pathophysiology
suggests that TRPM4 is an interesting drug
candidate for anti-cancer therapy. Our study
reports impaired migration, viability, proliferation,
cell cycle shift and a decrease in the adhesion of
cells, which lack TRPM4. The fact that ion
conductivity plays a role in viability further
supports the need for the development and
application of potent and specific TRPM4
blockers. Other mechanisms for TRPM4 i.e.
protein-protein interaction have lately been
reported [46,47] and will be investigated in the con-
text of prostate cancer hallmarks the future. Alto-
gether, our results add to the current interest in
the involvement of TRPM4 in cancer characteris-
tics, such as survival, migration, and adhesion.
Material and methods
Cell culture
DU145 cells were purchased from the American
Type Culture Collection (ATCC) and cultured in
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Minimum Essential Medium (MEM; Gibco)
supplemented with 10% v/v fetal calf serum
(FCS; Gibco), 1% v/v L-glutamine (Gibco), and
1% v/v Non-Essential Amino Acids (NEAA;
Gibco). Stable TRPM4 re-expressing cells were
cultured under the selective pressure of 0.5 lg/
mL Puromycin (Gibco). All cells were passaged
every 3–4 days.
Generation of knockout cell lines
TRPM4-knockout cell lines were generated using
CRISPR/Cas9 technique. Two gRNAs were
designed and approximately 10 kb were deleted
between exon 2 and exon 4 (Chr 19: 95975–
105719 9744bp). Sense and antisense oligos for
the gRNAs27 were cloned into pSpCas9(BB)-2A-
GFP or pU6-(BbsI)-CBh-Cas9-T2A-mCherry
according to the protocol from Zhang Lab.39 Cells
were transfected with the 4D-Nucleofactor X-unit
(Lonza) according to the manufacturer’s instruc-
tions. For each transfection of 2  106 cells, 2 mg
of each gRNA plasmid (gRNA4.1/gRNA4.2) was
used. Twenty-four hours post transfection the cells
were sorted for GFP/mCherry in the ASTRIOS flow
cytometry sorter (Beckman Coulter). Single cells
were seeded in 96-well plates for expansion, and
approximately two weeks later single cell clones
were transferred to 24-well plates. Around 100
clones were screened by genotyping (primer pairs;
see.27 Clones which showed the desired deletion in
both alleles were amplified and then stored in liquid
N2. Cell pellets were collected and further validated
with Western blot and quantitative RT-PCR.
Stable re-expression of TRPM4-wt and TRPM4-
D984A in TRPM4 knockout cells
DU145 TRPM4-K.O. clones 1 and clone 2 were
stably transfected with GFP-tagged TRPM4-wt or
TRPM4-D984A dominant-negative constructs to
generate stably TRPM4 re-expressing cells.
Control cells were transfected with a vector
expressing only GFP. The two TRPM4 constructs
were amplified from TRPM4-pMaxGFP and
TRPM4-D984A-pMaxGFP vectors and GFP was
amplified from TRPM4-pMaxGFP (primers listed
in27 and cloned into a piggyBac vector (5753 bp)
with ClonExpress Entry One Step Cloning Kit
(Lubio Science) according to the manufacturer’s
instructions. The cells were co-transfected with
0.5 mg transposase vector and 2 mg of correspond-
ing piggyBac vector using FuGENE transfection kit
(Promega). Following that, 72 h post transfection,
cell culture medium was replaced with selection
medium containing 1 mg/mL Puromycin (Gibco).
After two days with high selection pressure, trans-
fected cells were maintained in culture under a
lower selection pressure of 0.5 mg/mL Puromycin.
Successful re-expression of TRPM4 was confirmed
by green fluorescence of transfected cells.
Drug treatment
Three TRPM4 inhibitors were evaluated with
cellular assays: 4-chloro-2-(2-chlorophenoxy)
acetamido)benzoic acid (CBA), 4-chloro-2-(2-(4-c
hloro-2-methylphenoxy) propanamido) benzoic
acid (LBA), and 4-chloro-2-(1-naphthyloxyaceta
mido)benzoic acid (NBA). For use in the assays,
the compounds were dissolved in
dimeythylsulfoxide (DMSO). In control samples,
0.1% DMSO was applied. Proliferation and
migration were analyzed with the label-free
xCELLigence system (described below).
Western blot
Total cell lysate was prepared using M-PER
Mammalian Protein Extraction Reagent (Thermo
Scientific) plus protease inhibitor (Halt Protease
Inhibitor Cocktail) and benzonase nuclease.
Protein concentrations were measured with a
PierceTM BCA Protein Assay Kit (Thermo
Scientific), and 50 mg of total protein lysate was
loaded onto 10% SDS-PAGE gels (TGX
polyacrylamide gel, Bio-Rad). After proteins were
transferred to nitrocellulose membrane, TRPM4
was detected with a polyclonal rabbit antibody
previously described (1:500)26. b-actin, used as
endogenous control, was detected with mouse b-
actin antibody (1:2000; Cell Signaling Technology,
#3700). Both proteins were detected in combina-
tion with fluorescent secondary antibodies IRDye
Donkey anti-Mouse (#925-68022, LI-COR) and
IRDye 800CW Goat anti-Rabbit (#925-32211, LI-
COR). Protein expression was acquired with the
LICOR Odyssey Imaging System (LI-COR Biotech-
nology) and quantified using Image Studio Lite soft-
ware (LI-COR Biosciences).
Quantitative real-time PCR (qRT-PCR)
RNA was extracted using QIAshredder and the
RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. Reverse transcription
of 2 mg was performed with the High-Capacity
cDNA Reverse Transcription Kit (Thermo Fisher
Scientific). The cDNA was diluted 1:4 and
evaluated with quantitative expression analysis
using TaqMan Gene Expression Assay (Thermo
Fisher Scientific) on the ViiA 7 Real-Time PCR
System (Applied Biosystems/Thermo Fisher
Scientific) with the following program: 2 min
activation at 50 C, 10 min hold at 95 C, 40
cycles of 15 s denaturation at 95 C, and 1 min
annealing at 60 C. The qRT-PCR results were
analyzed with the DDCt method and expression
levels were normalized to two housekeeping
genes: RNA polymerase II (RNAPol II,
Hs00172187_m1) and TATA-binding protein
(TBP, Hs00427621_m1). TRPM4 mRNA
expression was quantified with Hs01026061_m1
primer-probe mix spanning exon 3–4.
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Electrophysiology
Whole-cell patch clamp experiments were
performed in LNCaP and DU145 cells at 22–25 C.
Voltage ramps of 50 ms, spanning 100 to
+100 mV from a holding potential of 0 mV, were
delivered every 2 seconds using the HEKA EPC-10
amplifier. Currents were acquired, digitized,
recorded, and analyzed with a HEKA EPC-10
amplifier, HEKA Patchmaster v2x53, and Igor Pro
6.37 software (WaveMetrics). Currents at 80 mV
and +80 mV, normalized to cell capacitance, were
plotted against time. The bath solution contained
140 mM NaCl, 0.5 mM CaCl2, 3 mM MgCl2, and
10 mM HEPES. Osmolality was adjusted to
300 mOsm with glucose and pH was set to 7.2 with
NaOH or HCl. In the N-methyl-D-glucamine
(NMDG+) bath solution, NaCl was replaced by
140 mM NMDG+. The internal pipette solution
contained 140 mM Cs-glutamate, 10 mM EDTA,
10 mM HEPES, and 8 mM NaCl. WEBMAXC
STANDARD was used for calculation of free Mg2+
(3 mM) and Ca2+ (10 mM) in the internal pipette
solution.40 Patch pipettes with a resistance of 2–3
MX were used in these experiments.
Viability and proliferation assays
RealTime Glo MT Cell Viability Assay (Promega)
was used to study cell viability kinetics. Cells were
seeded in white 96-well plates at a density of
2  103 cells per well. For this assay, 50 mL of
assay reagent mix was added to 50 mL of cells in
standard culture medium. Luminescence was
assessed every hour over 72 h with a Tecan
SparkTM 10 M multimode microplate reader
(Tecan), utilizing the heat- and gas-control and
humidity chamber. Cells were always passaged
the day before experimental set up. Each
experimental condition was measured in triplicate
and repeated three times. All experiments were
normalized to the first measured value.
Cell proliferation was assessed with
xCELLigence E-Plates on the xCELLigence
RTCA DP system (ACEA Biosciences), an assay
that records changes in impedance as the cells
adhere to the surface of the plate. For the
proliferation assay, 1  104 cells were seeded per
well and impedance was measured every 15 min
over 72 h. This assay was also used to study the
adhesion of cells during the initial hours. Cells
were always passaged the day before the
experiment was set up and each experiment was
repeated a minimum of three times. Statistical
significance for viability and proliferation assays
was analyzed with the Friedman test and Dunn’s
test for multiple comparison.
Transwell migration assays
Prior to the migration assay, cells were incubated
with 1 mM CellTrackerTM Green CMFDA Dye
(Invitrogen) in serum-free medium for 30 min.
After replacing the medium with fresh serum-free
medium, the top chamber of the 24-well plate
containing Fluorblok inserts (Corning) was loaded
with 5  104 fluorescent cells. The bottom
chamber of the 24-well plate was filled with
normal culture medium with 10% FCS as
attractant. Relative fluorescence was measured in
top and bottom readout mode every hour over
25 h with the Tecan SparkTM 10 M multimode
microplate reader (Tecan) utilizing the gas control
and heat settings. The migratory potential of the
cells was calculated as the ratio of cells migrating
through the pores of the chamber relative to the
number of cells remaining in the top chamber.
The xCELLigence system offers a label-free
transwell migration assay. For this assay, 4  104
cells were seeded in serum-free media in the top
chamber of the xCELLigence  CIM-Plates
(ACEA Biosciences). Standard culture medium
with 10% FCS as attractant was used in the
bottom chamber. Whenever a compound was
tested, the inhibitor was added to the top
chamber. Impedance was measured in 15 min
intervals for 25 h with the xCELLigence  RTCA
DP device. Statistical significance for the two
transwell migration assays was analyzed with the
Friedman test and Dunn’s test for multiple
comparison.
IncuCyte live cell imaging
The IncuCyte S3 system (Essen BioScience)
was used to analyze cell confluence, cell
adhesion, and the average size of objects (cells).
Cells were trypsinized, counted, and diluted to
0.5  105, 1  105, and 2  105 cells per well in
a 24-well plate. Acquisition was initiated
immediately after seeding. Phase contrast images
were acquired every 30 min for 24 h, at 10
magnification. All cells were passaged the day
before the experiment begun to be in the same
growth phase and confluence. Images were
analyzed using IncuCyte S3 Software (Essen
BioScience). The experiment was repeated at
least three times. The Friedman test and Dunn’s
test for multiple comparison were used for
statistical evaluation.
Cell cycle analysis
Propidium iodide (PI) staining was performed
with a Propidium Iodide Flow Cytometry Kit
(Abcam) according to the standard protocol. Cells
were counted and seeded into 6-well plates at a
density of 3  105 per well the day before
fixation. On the following day, cells were collected
and fixed in 66% ice-cold EtOH and stored at 4 
C overnight or until FACS analysis. Cell cycle
distribution was analyzed with BD LSR II flow
cytometer (BD Bioscience) and FACSDiva
Software (BD Bioscience). Collected data were
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analyzed with FlowJo v10 (FlowJo). Each
experiment was repeated at least three times.
Statistical significance was analyzed with one-way
ANOVA and the Holm-Sidiak’ multiple comparison
test.
Immunofluorescence and staining
quantification
A prostate cancer tissue microarray (TMA) of 210
patient samples assembled from the European
Multicenter Prostate Cancer Clinical and
Translational Research (EMPaCT) initiative (Ref
PMID: 28753838) was used for
immunofluorescence (IF) staining. TMA sections
were stained for TRPM4 expression by IF using
the Tyramide SuperBoostTM kit (Invitrogen). The
TMA sections were incubated at 55 C 2 h prior
to deparaffinization and antigen retrieval in boiling
citrate buffer. The following IF staining was
performed according to the manufacturer’s
protocol: In short, endogenous peroxidase activity
was quenched by 3% H2O2 and sections blocked
in blocking buffer (10% goat serum) for 1 hour
before overnight incubation with the primary
polyclonal rabbit antibody against TRPM4
(generated by Pineda, previously described by.26
The next day, the sections were incubated with
poly-HRP-conjugated goat anti-rabbit IgG antibody
and tyramide labelling was performed for 5 min.
Nuclear counterstaining with DAPI (Thermo Fisher
Scientific) was performed and the slides were
scanned by a Pannoramic 250 Flash III slide scan-
ner (3D Histech Ltd). IF staining was scored as
negative (0) or positive (1–4) by manually counting
TRPM4-positive areas, as follows: 0 = no staining;
1 = staining in one area; 2 = staining in two areas;
3 = staining in three areas; 4 = staining in more
than three areas.
Survival analysis
Kaplan-Meier curves to illustrate the progression
of the stratified scoring groups in the prostate
cancer cases were calculated using the “survfit”
function and the global log-rank test using the
Survival R package.41,42 For pairwise comparison,
p-value was estimated by the log-rank test and
adjusted with the Benjamini–Hochberg (BH)
method. For all parameters, if no information on
patient outcome was available, information at last
follow-up was used. Clinical progression was
defined as metastasis or local recurrence. Disease
progression was defined by combining any form of
recurrence (PSA and clinical progression). Data
representation and graphical plots were generated
using the ggplot2 R package.43 Data analysis was
done using RStudio version 1.1.46344 and R ver-
sion 3.5.3.45
Statistical analysis
Cellular assays were statistically evaluated with
the Friedman test and Dunn’s test for multiple
comparison. FACS cell cycle data were analyzed
with one-way ANOVA and the Holm–Sidak
multiple comparison test. All analyses consisted
of at least three independent experiments. All
data are displayed as mean +/ SEM unless
indicated otherwise. Statistical analysis was
performed on GraphPad Prism8. Experiments
with a p-value < 0.05 were considered significant.
The survival analysis was performed on RStudio
version 1.1.463.
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